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Abstract
Background: Type 2 diabetes mellitus (T2DM) is a progressive chronic disease associated with severe microvascular
and macrovascular complications.
Our aim is to assess the real world effectiveness of SGT" inhibitors in achieving metabolic therapeutic goals.
Methods: A retrospective, observational study. Inclusion criteria for patients were a previous diagnosis of type 2
diabetes mellitus, age > 18 years, patients receiving either dapagliflozin 10 mg and/or canagliflozin 300 mg. We
excluded pregnant patients, patients with type 1 diabetes mellitus and acute metabolic complications of diabetes.
Patients included in the analysis were enrolled in a health plan at least 6 months prior to the index date (baseline
period) and in the 6 months following the index date (follow-up period). Achievement of glycated hemoglobin goals
were established as <7%.
Results: We screened 2870 Mexican patients; 288 (10.03% received SGLT2 inhibitors). Mean age for both groups of
patients was 57.68 ± 11.06 years. The dapagliflozin control rate was 19.56% and the canagliflozin control rate 18.96%.
Monotherapy with SGLT2 inhibitors was used in 21 patients (6.25%). Overall HbA1c goals were met in 56 patients (19.
44%) with similar results with dapagliflozin or canagliflozin. The combination of SGLT2 inhibitors and sulfonylureas had
the highest control rate (30.30%) compared to other regimens. Monotherapy was present in 6.25%. Insulin requirement
was associated with poor control (2.8% vs. 18.05%, P < 0.05, 95% CI [0.07, 0.84]). Combination therapy with DPP4
inhibitors was associated with better control (P < 0.05, 95% CI, [1.10, 3.92]).
Conclusion: No difference between the drugs was observed. Real-world effectiveness data of SGLT2 inhibitors show
that the percentage of patients reaching metabolic goals is low. SLGT2 inhibitors were used more frequently as
combined therapy.
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Background
Type 2 diabetes mellitus (T2DM) is a progressive
chronic disease characterized by insulin resistance and a
progressive insulin secretory defect associated with se-
vere microvascular and macrovascular complications [1].
Until recently there was little evidence for cardiovascular
risk reduction with glucose-lowering therapies in type 2
diabetes (T2DM). However, within the last year the
results of two trials (EMPA-REG and LEADER) have
demonstrated substantial cardiovascular benefit with
two agents: SGLT2 inhibitor empagliflozin and
glucagon-like peptide-1 (GLP-1) analogue liraglutide.
Many large randomized control trials have demonstrated
a significant reduction in microvascular events in
patients treated with hypoglycemic agents leading to a
reduced HbA1C [2].
The progressive nature of the disease means that most
patients require increasingly intensive pharmacologic
interventions often with multiple classes of diabetes
medications. Given this issue, the American Diabetes
Association (ADA) guidelines recommend HbA1C
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therapeutic goals <7% [3] to reduce morbidity and
complications in T2DM.
A class of oral antihyperglycemic agents (AHA) that
has the potential to address these needs is now available.
Sodium glucose co-transporter type 2 (SLGT2) inhibi-
tors are becoming a promising therapy for T2DM. These
drugs reduce hyperglycemia by blocking renal glucose
reabsorption, in the proximal tubule of the kidney. This
induces glucosuria which lowers serum glucose and also
induces diuresis [3].
A systematic review evaluating the effectiveness of
SGLT2 has shown that HbA1C is decreased in a range
of 0.32% to 1.17% [4]. Other effects reported are a slight
reduction of triglycerides [5], blood pressure, and weight,
and a low potential for hypoglycemia [6, 7]. Recently,
the EMPA- REG study showed that patients, with a
high-risk for CVD, receiving empagliflozin had a lower
rate of deaths from CVD [6].
However, few studies [2, 4, 5] have been conducted
evaluating the effectiveness of SGLT2 inhibitors, either
combined with another AHA or as monotherapy, for
reaching ADA HbA1C therapeutic goals in a real-world
setting.
The objective of this study is to assess the effectiveness
of SLGT2 inhibitors (dapagliflozin, canagliflozin) in
achieving HbA1C goals in patients with T2DM in a
private Mexican outpatient clinic.
Methods
This cohort study used patient data obtained from a
large health plan database from an outpatient clinic
(Hospital Clinica Nova, San Nicolas de los Garza, Nuevo
Leon, Mexico) during 2014–2016. Inclusion criteria were
a diagnosis of T2DM, age > 18 years, and receiving ei-
ther dapagliflozin 10 mg (Forxiga®, AstraZeneca) or
canagliflozin 300 mg (Invokana®, Janssen) with or with-
out background metformin therapy and not achieving
glycemic targets. We excluded pregnant patients, pa-
tients with type 1 diabetes mellitus, and patients with
acute metabolic complications (diabetic ketoacidosis,
hyperglycemic hyperosmolar state) and those with poor
treatment adherence from primary analysis, the other in-
hibitor drug class (empagliflozin) it’s currently not avail-
able in our clinic. Baseline characteristics (age, gender,
comorbidity, drug use, and insulin requirements) were
reported. Achievement of glycated hemoglobin goals was
established as <7% following ADA 2016 recommenda-
tions [3]. Patients included in the analysis were enrolled
in the health plan for at least 6 months prior to the
index date (baseline period) and 6 months following the
index date (follow-up period). The study was approved
by the local ethics committee. Statistics were reported as
frequencies, percentages, central tendency, and disper-
sion measures. For continuous variables, normality
testing was done using the Shapiro-Wilk test. For testing
difference in means, a two sample t-test or Mann
Whitney U test was used. For discrete variables, Pearson
χ2 or the Fisher exact test was used as needed. A P value
<0.05 was considered statistically significant. Statistical
analysis was made using R software v 3.3.1 [7].
Results
We screened 2870 patients; of these 288 (10.03%)
received SGLT2 inhibitor therapy. Monotherapy with
SGLT2 inhibitors was present in 21 (6.25%). Metformin
was the most frequent AHA (57.29%) combined with
SGLT2 inhibitors. Most patients used at least 2
additional different antidiabetic drugs (46.87%). Co-
morbidities were present in 38 (13.19%) patients. Fifty-
three (18.40%) patients required insulin.
In the dapagliflozin group, mean patient age was
57.68 ± 11.06 years (range 34 to 82). According to gen-
der, there were 135 (58.69%) women and 95 (41.3%)
men. HbA1C goals were met in 19.56% of patients. In
the canagliflozin group, 58 cases were included. Mean
patient age was 58 ± 10.56 years (range 30 to 83). Ac-
cording to gender, 28 (50%) patients were men and 28
(50%) women. HbA1C goals were met in 18.96% of pa-
tients. The canagliflozin group had an average reduction
on the HbAC1 levels from 9.72% to 8.69% and the dapa-
gliflozin group from 9.90% to 8.83%.Both therapies had
similar reductions of HbA1C with no significant differ-
ence between them. Overall HbA1C goals were met in
56 (19.44%) patients. The combination of SGLT2 inhibi-
tors with sulfonylureas, and dipeptidyl peptidase 4
(DPP4) inhibitors had the highest control rate (30.30%/
26.55%) compared with other regimens. Mild weight loss
was reported (3.2 vs. 2.7 kg, P = 0.657) with no signifi-
cant difference between dapagliflozin and canagliflozin.
Patients with insulin requirement had poorer control
(7.75%) than non-insulin users (22.13%, P < 0.05, 95% CI
[0.07, 0.84]). No severe hypoglycemic events, ketoacido-
sis, and severe urinary tract infections were reported.
However, a higher frequency of urinary tract infections
(OR 2.3, 95% CI [1.81, 2.78]) and mycotic infections (OR
4.02, 95% CI [4.02, 5.18]) in women, (OR 3.17 95% CI
[2.63, 3.71]) and men in the treated group was reported.
Blood pressure and lipid profiles were not included in
the analysis due to incomplete data. All results are
summarized in Table 1.
Discussion
In our clinic, the use of SGLT2 doesn’t correspond to a
first line treatment. Despite the decrease in HbA1C, few
patients achieved ADA glycated hemoglobin goals.
Second-line pharmacotherapy selection for patients
with T2DM is debated. Experts recommended patient-
specific considerations. SGLT2 are a promising new class
Tamez-Perez et al. Journal of Diabetes & Metabolic Disorders  (2017) 16:27 Page 2 of 5
of diabetes pharmacotherapy that particularly shows fa-
vorable effects on weight, low potential of hypoglycemia
and a reduction of cardiovascular risk [2, 4, 5].
We observed a significant reduction of HbA1C,
similar to a trend in the use of SGLT2 inhibitors as
combination therapy compared with previous studies,
lowering HbA1C by 1%–1.5%. The majority of clin-
ical trials evaluate moderately uncontrolled diabetes
and there is limited data available describing the effi-
cacy of these drugs in patients with poor metabolic
control; however, the reduction in glucotoxicity with
SGLT2 and improvement insulin sensitivity may
result in an increase benefit in patients with a higher
HbA1C [4, 5]. We noted a steady increase in control
rates in patients receiving SGLT2 inhibitors in
addition to sulfonylureas and DPP4 inhibitors, but
our results are less than those of controlled clinical
trials, attributable to not following current guidelines
that recommend stepwise intensification. Rosentock
et al. reported a better response in HbA1C goals
with triple therapy saxagliptin, metformin and dapa-
gliflozin (41%) and the dual addition of saxagliptin
and dapagliflozin (22%). They reported a reduction of
HbA1C levels of 1.47% [8]. This HbA1C reduction in
the dual add-on group was less than the summation of the
reductions seen in the monotherapy arms. No significant
differences in control between canagliflozin and dapagli-
flozin were noted, probably due to class effect. In a recent
study, empagliflozin has been noted to reduce CVD risk
[6]; however, it was not evaluated here due to unavailabil-
ity. Metformin is recommended as first- line treatment for
patients with T2DM due to its well-established efficacy,
safety, low cost, and data demonstrating a reduction in
risk of cardiovascular events. SGLT2 as monotherapy is an
option in patients with contraindications to the use of
metformin or who do not tolerate metformin; in our
group alone, this was considered in only 21 patients
(6.25%).
Merocvi and cols reported that SGLT2 inhibitors as
monotherapy improve insulin sensitivity and reduce the
Table 1 ADA Hb1Ac goals in patients with type 2 diabetes
Variable HbA1c < 7 HbA1c > 7 p 95% CI OR
n 56 (19.44) 232 (80.55) – –
Age (years) 56.89 ± 10.62 57.99 ± 10.98 0.4938c [-2.07,4.26]a –
Female (%) 29 (17.68) 135 (82.32) 0.472564d [0.69,2.43] 1.3
Male (%) 27 (21.77) 97 (78.23)
Insulin Requirement (%)
No 52 (22.13) 183 (77.87)
Yes 4 (7.55) 49 (92.45) <0.05a, e [0.07,0.84] 0.29
Combination with other ant diabetics (%)
Saxaglyptin 29 (26.85) 79 (73.15) <0.05a, d [1.1,3.92] 2.08
Sulfonylureas 10 (30.3) 23 (69.7) 0.1495d [0.78,4.67] 1.98
Metformin 38 (23.03) 127 (76.97) 0.103d [0.91,3.44] 1.75
Pioglitazone 8 (23.53) 26 (76.47) 0.6817d [0.49,3.24] 1.32
Acarbose 6 (21.43) 22 (78.57) 0.9777d [0.36,3.11] 1.15
Monotherapy 21 (20.39) 82 (79.61) 0.8834d [0.57,2.08] 1.1
Sitagliptine 18 ( 12.59 ) 125 (87.41) <0.01b,d [0.21,0.78] 0.41
Drug use (%)
Statin 30 (18.75) 130 (81.25) 0.854714d [0.48,1.7] 0.91
Aspirin 20 (15.5) 109 (84.5) 0.16998 d [0.32,1.19] 0.63
Comorbidity (%)
Dyslipidemia 6 (17.65) 28 (82.35) 0.959111d [0.28,2.31] 0.87
Neuropathy 0 ( 0 ) 3 (100) 0.902737e [0,10.1] –
Nephropathy 0 ( 0 ) 1 (100) 1e [0,161.17]
95% CI 95% confidence interval; ORodds ratio
aP < 0.05
bP < 0.01
ctwo-sample t-test
dPearson χ2
eFisher´s exact test
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progressive loss of beta-cell function and insulin resistance;
unfortunately, limited long- term data are available [9].
Weight loss is a desirable outcome in most patients
with T2DM due to the positive impact of glycemic
control, insulin sensitivity, and comorbidity. Our study
results do not differ importantly from other publications
[3, 4]. Weight loss appears to be sustained for up to
102 weeks [4, 6].
The positive effects on cardiovascular outcomes are
highly promising. Long term data, including primary
cardiovascular prevention populations and utilizing
other SGLT2, will be needed to fully assess the cardio-
vascular outcomes with this class of medications.
SGLT2 inhibitors have been associated with an
increased risk of genitourinary infections and polyuria
due to increased glucose concentrations in the urine
[10–12]. Our rates appear modestly increased and no
severe adverse effects were reported. A recent study
comparing trial against real world data concluded that
extrapolation of the trials and the results in the real
world do not match [2]. Further research is needed to
clarify and validate the benefits of SGLT2 at the transla-
tional biology level as well as its impact on clinical
medicine [13].
We must become familiar with autonomous medical
education and perform precision medicine. In diabetes,
the selection of treatment should be patient specific and
incorporate knowledge of potential adverse effects, the
required HbA1C reduction to archive the goal, cost,
weight consideration, co-morbid medication conditions,
and patient preferences.
Given the cost of this group class therapy, it should be
stopped in patients that fail to respond.
An important strength of the study is the comparison
of the overall effectiveness of SGLT2 inhibitors alone or
combined in a private clinic setting where all the physi-
cians are internal medicine specialists in a real-world
setting. Also, the study evaluated the impact of multiple
combined regimens of SGLT2 inhibitors on glycemic
goals. The limitations of the study include that data was
retrieved from electronic medical records that contain
limited data for important measurements such as blood
pressure or lipid profile of a small sample of patients this
has been analyzed recently and we accept that there is a
need for real life pragmatic trials; the limitations are
problematic [14]. Differences in the size of population
analyzed in the dapagliflozin and canagliflozin groups
appear due to when each drug was introduced to the
clinic and which one it’s prescribe by each physician.
Empagliflozin was excluded from the analysis because
it’s fairly new option in our clinic.
Also, patients were treated in a secondary-level out-
patient clinic. HbA1c measurements were made only
during a 6-month period, and the study assessed control
outcomes without reporting adjustments of important
comorbidities such as chronic kidney disease, estimated
glomerular filtration rate reduction may negatively affect
the efficacy of SGLT2 inhibitors [15].
Conclusions
The results were similar for both drugs. Our results are
not comparable to clinical trials, which should be per-
formed carefully in the real-world and the effectiveness
data of SGLT2 inhibitors show that the percentage of
patients reaching metabolic goals is low. SLGT2 inhibi-
tors were used more frequently as combined therapy.
Further research is needed to validate these findings in
other T2DM patient populations.
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